Charles River Laboratories International Inc (CRL) reported Q3 2025 earnings per share (EPS) of $2.43, surpassing the consensus estimate of $2.36 by $0.07. Revenue matched expectations at $1.0 billion.
The company will host an earnings conference call at BMO to discuss these results and provide additional insights into its operational performance.
This earnings report highlights Charles River Laboratories' financial health, reflecting stronger-than-anticipated business fundamentals. Investors are encouraged to review the full earnings release and listen to management's commentary for further context on the quarter's performance and future outlook.
Headquartered in Wilmington, Massachusetts, Charles River Laboratories engages in providing essential products and services to pharmaceutical and biotechnology companies, as well as government agencies and academic institutions globally. The company employs approximately 18,600 full-time employees and went public on June 23, 2000. Its segments include Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions.
Looking ahead, the company is set to report its next earnings on May 4, 2026, with an estimated EPS of $2.5888 and revenue expected to remain at $1.0 billion.